Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma
Oncotarget · 2025
DOI: 10.18632/oncotarget.28721 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Oncotarget, 2025. Verfasst von Leonardo Gomes da Fonseca und 19 weiteren Autor:innen. Beteiligte Einrichtung: Instituto do Cancer do Estado de São Paulo, Hospital das Clínicas, Universidade São Paulo, Brazil. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Patientensicherheit
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto do Cancer do Estado de São Paulo, Hospital das Clínicas, Universidade São Paulo, Brazil.
- Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Argentina.
- Department of Hepatology, Hospital Alemán, Argentina.
- Department of Hepatology and Liver Transplantation, Hospital Italiano de Buenos Aires, Argentina.
- Department of Liver Transplantation, Sanatorio Sagrado Corazón, Argentina.
- Department of Hepatology, Fundación Cardioinfantil, Colombia.
Zitieren
APA
da Fonseca, L. G., Piñero, F., Anders, M., Bermudez, C., Demirdjian, E., Varón, A., Perez, D., Rodriguez, J., Beltrán, O., Ridruejo, E., Caballini, P., Araujo, A., Florez, J. D. T., Marín, J. I., Villa, M., Orozco, F., Poniachik, J., Marciano, S., Bessone, F., & Mendizabal, M. (2025). Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma. Oncotarget. https://doi.org/10.18632/oncotarget.28721
Vancouver
da Fonseca LG, Piñero F, Anders M, Bermudez C, Demirdjian E, Varón A, et al. Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma. Oncotarget. 2025. doi:10.18632/oncotarget.28721
BibTeX
@article{daFonseca2025,
author = {da Fonseca, Leonardo Gomes and Piñero, Federico and Anders, Margarita and Bermudez, Carla and Demirdjian, Ezequiel and Varón, Adriana and Perez, Daniela and Rodriguez, Jorge and Beltrán, Oscar and Ridruejo, Ezequiel and Caballini, Pablo and Araujo, Alexandre and Florez, Juan Diego Torres and Marín, Juan Ignacio and Villa, Marina and Orozco, Federico and Poniachik, Jaime and Marciano, Sebastián and Bessone, Fernando and Mendizabal, Manuel},
title = {Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma},
journal = {Oncotarget},
year = {2025},
doi = {10.18632/oncotarget.28721}
}
EUVIMED